Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)

José Falantes, Lisa Pleyer, Sylvain Thépot, António M. Almeida, Luca Maurillo, Violeta Martínez-Robles, Reinhard Stauder, Raphael Itzykson, Ricardo Pinto, Adriano Venditti, Joan Bargay, Sonja Burgstaller, María Pilar Martínez, Valerie Seegers, Emilia Cortesão, María Ángeles Foncillas, Claude Gardin, Pau Montesinos, Pellegrino Musto, Pierre FenauxRichard Greil, Miguel Angel Sanz, Fernando Ramos

Research output: Contribution to journalArticle

Abstract

Azacitidine (AZA) prolonged overall survival (OS) in the AZA-AML-001 trial. However, few subjects were randomized to AZA or intensive chemotherapy (IC). The Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) developed a score for older AML patients receiving IC or non-intensive regimens, whereas the E-ALMA study validated a score for survival and response in elderly patients receiving AZA in daily practice. Both identified three groups with different risk estimates. This analysis evaluates the efficacy of frontline AZA in older AML patients (N = 710) unfit for IC from different national registries (E-ALMA + series) stratified by the MRC/LRF risk score. Median OS of patients categorized as good, standard and poor-risk groups by the MRC/LRF score was 13.4 (95% CI, 10.8–16), 12.4 (95% CI, 9.9–14.8), and 8.1 months (95% CI, 7–9.1), respectively (p = .0001). In conclusion, this is the largest retrospective cohort of older AML patients treated with AZA.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - Aug 25 2017

Fingerprint

Azacitidine
Life Change Events
Acute Myeloid Leukemia
Biomedical Research
Leukemia
Research
Drug Therapy
Survival
Registries

Keywords

  • Acute myeloid leukemia
  • azacitidine
  • E-ALMA+
  • elderly
  • MRC/LRF risk score

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score : results from the expanded international E-ALMA series (E-ALMA+). / Falantes, José; Pleyer, Lisa; Thépot, Sylvain; Almeida, António M.; Maurillo, Luca; Martínez-Robles, Violeta; Stauder, Reinhard; Itzykson, Raphael; Pinto, Ricardo; Venditti, Adriano; Bargay, Joan; Burgstaller, Sonja; Martínez, María Pilar; Seegers, Valerie; Cortesão, Emilia; Foncillas, María Ángeles; Gardin, Claude; Montesinos, Pau; Musto, Pellegrino; Fenaux, Pierre; Greil, Richard; Sanz, Miguel Angel; Ramos, Fernando.

In: Leukemia and Lymphoma, 25.08.2017, p. 1-8.

Research output: Contribution to journalArticle

Falantes, J, Pleyer, L, Thépot, S, Almeida, AM, Maurillo, L, Martínez-Robles, V, Stauder, R, Itzykson, R, Pinto, R, Venditti, A, Bargay, J, Burgstaller, S, Martínez, MP, Seegers, V, Cortesão, E, Foncillas, MÁ, Gardin, C, Montesinos, P, Musto, P, Fenaux, P, Greil, R, Sanz, MA & Ramos, F 2017, 'Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)', Leukemia and Lymphoma, pp. 1-8. https://doi.org/10.1080/10428194.2017.1365854
Falantes, José ; Pleyer, Lisa ; Thépot, Sylvain ; Almeida, António M. ; Maurillo, Luca ; Martínez-Robles, Violeta ; Stauder, Reinhard ; Itzykson, Raphael ; Pinto, Ricardo ; Venditti, Adriano ; Bargay, Joan ; Burgstaller, Sonja ; Martínez, María Pilar ; Seegers, Valerie ; Cortesão, Emilia ; Foncillas, María Ángeles ; Gardin, Claude ; Montesinos, Pau ; Musto, Pellegrino ; Fenaux, Pierre ; Greil, Richard ; Sanz, Miguel Angel ; Ramos, Fernando. / Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score : results from the expanded international E-ALMA series (E-ALMA+). In: Leukemia and Lymphoma. 2017 ; pp. 1-8.
@article{f5923378b968471f98d13f572e850e26,
title = "Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)",
abstract = "Azacitidine (AZA) prolonged overall survival (OS) in the AZA-AML-001 trial. However, few subjects were randomized to AZA or intensive chemotherapy (IC). The Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) developed a score for older AML patients receiving IC or non-intensive regimens, whereas the E-ALMA study validated a score for survival and response in elderly patients receiving AZA in daily practice. Both identified three groups with different risk estimates. This analysis evaluates the efficacy of frontline AZA in older AML patients (N = 710) unfit for IC from different national registries (E-ALMA + series) stratified by the MRC/LRF risk score. Median OS of patients categorized as good, standard and poor-risk groups by the MRC/LRF score was 13.4 (95{\%} CI, 10.8–16), 12.4 (95{\%} CI, 9.9–14.8), and 8.1 months (95{\%} CI, 7–9.1), respectively (p = .0001). In conclusion, this is the largest retrospective cohort of older AML patients treated with AZA.",
keywords = "Acute myeloid leukemia, azacitidine, E-ALMA+, elderly, MRC/LRF risk score",
author = "Jos{\'e} Falantes and Lisa Pleyer and Sylvain Th{\'e}pot and Almeida, {Ant{\'o}nio M.} and Luca Maurillo and Violeta Mart{\'i}nez-Robles and Reinhard Stauder and Raphael Itzykson and Ricardo Pinto and Adriano Venditti and Joan Bargay and Sonja Burgstaller and Mart{\'i}nez, {Mar{\'i}a Pilar} and Valerie Seegers and Emilia Cortes{\~a}o and Foncillas, {Mar{\'i}a {\'A}ngeles} and Claude Gardin and Pau Montesinos and Pellegrino Musto and Pierre Fenaux and Richard Greil and Sanz, {Miguel Angel} and Fernando Ramos",
year = "2017",
month = "8",
day = "25",
doi = "10.1080/10428194.2017.1365854",
language = "English",
pages = "1--8",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score

T2 - results from the expanded international E-ALMA series (E-ALMA+)

AU - Falantes, José

AU - Pleyer, Lisa

AU - Thépot, Sylvain

AU - Almeida, António M.

AU - Maurillo, Luca

AU - Martínez-Robles, Violeta

AU - Stauder, Reinhard

AU - Itzykson, Raphael

AU - Pinto, Ricardo

AU - Venditti, Adriano

AU - Bargay, Joan

AU - Burgstaller, Sonja

AU - Martínez, María Pilar

AU - Seegers, Valerie

AU - Cortesão, Emilia

AU - Foncillas, María Ángeles

AU - Gardin, Claude

AU - Montesinos, Pau

AU - Musto, Pellegrino

AU - Fenaux, Pierre

AU - Greil, Richard

AU - Sanz, Miguel Angel

AU - Ramos, Fernando

PY - 2017/8/25

Y1 - 2017/8/25

N2 - Azacitidine (AZA) prolonged overall survival (OS) in the AZA-AML-001 trial. However, few subjects were randomized to AZA or intensive chemotherapy (IC). The Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) developed a score for older AML patients receiving IC or non-intensive regimens, whereas the E-ALMA study validated a score for survival and response in elderly patients receiving AZA in daily practice. Both identified three groups with different risk estimates. This analysis evaluates the efficacy of frontline AZA in older AML patients (N = 710) unfit for IC from different national registries (E-ALMA + series) stratified by the MRC/LRF risk score. Median OS of patients categorized as good, standard and poor-risk groups by the MRC/LRF score was 13.4 (95% CI, 10.8–16), 12.4 (95% CI, 9.9–14.8), and 8.1 months (95% CI, 7–9.1), respectively (p = .0001). In conclusion, this is the largest retrospective cohort of older AML patients treated with AZA.

AB - Azacitidine (AZA) prolonged overall survival (OS) in the AZA-AML-001 trial. However, few subjects were randomized to AZA or intensive chemotherapy (IC). The Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) developed a score for older AML patients receiving IC or non-intensive regimens, whereas the E-ALMA study validated a score for survival and response in elderly patients receiving AZA in daily practice. Both identified three groups with different risk estimates. This analysis evaluates the efficacy of frontline AZA in older AML patients (N = 710) unfit for IC from different national registries (E-ALMA + series) stratified by the MRC/LRF risk score. Median OS of patients categorized as good, standard and poor-risk groups by the MRC/LRF score was 13.4 (95% CI, 10.8–16), 12.4 (95% CI, 9.9–14.8), and 8.1 months (95% CI, 7–9.1), respectively (p = .0001). In conclusion, this is the largest retrospective cohort of older AML patients treated with AZA.

KW - Acute myeloid leukemia

KW - azacitidine

KW - E-ALMA+

KW - elderly

KW - MRC/LRF risk score

UR - http://www.scopus.com/inward/record.url?scp=85028547438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028547438&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1365854

DO - 10.1080/10428194.2017.1365854

M3 - Article

AN - SCOPUS:85028547438

SP - 1

EP - 8

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -